Overview


According to FutureWise analysis the market for anti-obesity drugs in 2023 is US$ 1.78 billion, and is expected to reach US$ 4.08 billion by 2031 at a CAGR of 10.90%.

Anti-obesity drugs, also known as weight loss or anti-obesity medications, are pharmaceutical agents designed to help individuals manage their weight by suppressing appetite, reducing absorption of nutrients, or increasing metabolism. Obesity stimulates the incidence of conditions such as type 2 diabetes and cardiovascular diseases. It also increases the risk of death due to cancer of the oesophagus, colon and liver, rectum, gallbladder, pancreas, and kidney. These drugs are generally prescribed for individuals with a BMI (mass index) of 30 or higher, which is considered obese, or a BMI of 27 or higher with obesity-related conditions like dyslipidemia, high blood pressure, or diabetes.

Anti-obesity drugs can be classified based on their mechanisms of action, including peripherally acting drugs and centrally acting drugs. Centrally-acting drugs are medications that lower heart rate and relieve blood pressure. They function by blocking the signals from the brain to the nervous system, increasing the heart rate and narrowing the blood vessels. Consequently, the heart exerts less force in its pumping action. This promotes smoother blood flow through the body's veins and arteries and also lowers blood pressure. Central-acting drugs may also use to prevent, treat, or improve symptoms of other health conditions, such as attention-deficit/hyperactivity disorder (ADHD), drug withdrawal, such as from opioid pain medicines, or hot flashes in menopause. Further, peripherally acting drugs influence processes outside the central nervous system. These drugs primarily target digestive processes or metabolic functions.

FutureWise Market Research has published a report that provides an insightful analysis anti-obesity drugs market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, anti-obesity drugs market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Arena Pharmaceuticals Inc.
  • Alizyme
  • Bayer AG
  • Bristol-Myers Squibb
  • Currax Pharmaceuticals LLC
  • Eisai Co. Ltd
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • MerckCo. Inc.
  • Norgine BV
  • Novo Nordisk AS
  • Orexigen Therapeutics
  • Pfizer Inc.
  • Rhythm Pharmaceuticals
  • Takeda Pharmaceuticals
  • Vivus Inc.
  • Zafgan
  • Zydus Cadila

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Anti-obesity Drugs Market:

  • In October 2022, Lilly received Fast Track Designation from the US FDA for tirzepatide. This novel drug is being studied to treat anti-obesity and overweight in adults.
     
  • In June 2021, the US FDA approved the use of the drug Semaglutide 2.4 mg in the chronic weight management of adults struggling with obesity or being overweight, with at least one weight-related disease, such as cholesterol, high blood pressure or type 2 diabetes (T2D). This approval allows its use alongside a reduced-calorie diet and increased physical activity.

The increasing global obesity epidemic is a significant driver in the anti-obesity drugs market over the forecast period. With the rising obesity rates worldwide, the need for effective treatments is essential. This surge in obesity cases is attributed to complex factors like sedentary lifestyles, unhealthy dietary habits, and genetic propensities. As individuals struggle with managing their weight, there is increasing demand for pharmaceutical solutions that may offer tangible, sustainable outcomes, further propelling market growth. Additionally, the growing prevalence of government efforts and initiatives influences the anti-obesity drugs market. Public health campaigns' stringent regulations on food labeling enhance transparency, enabling consumers to make more informed dietary options, and initiatives to encourage healthier lifestyles might positively impact the target market. Also, recent advances in understanding molecular gut-brain communication have ignited interest in next-generation Anti-Obesity Medications (AOMs). These advanced drugs hold the promise to safely achieve and endure body weight reduction. This improved understanding of the intricate interplay between the gastrointestinal tract and the brain opens up new avenues for drug development, further driving the growth of the anti-obesity drug market. However, the adverse side effects and safety concerns may pose significant hurdles to the anti-obesity market. While these drugs hold promise in weight management, the inherent risks may give rise to uncertainty among patients and healthcare professionals. Concerns regarding side effects and long-term safety may drain trust in these treatments, potentially hindering their widespread adoption. Therefore, hampering the growth of the anti-obesity drugs market during the projection period.

By Mechanism of Action

  • Peripherally Acting Drugs
  • Centrally Acting Drugs

By Drug Type

  • Prescription Drugs
  • OTC Drugs

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Owing to the increasing prevalence of obesity globally, advancements in pharmaceutical research, adoption of advanced medical solutions, the development of innovative and effective anti-obesity medications, integration of precision medicine, and genomics for developing personalized anti-obesity treatments in the region will likely drive market growth. Additionally, due to the presence of key market players in the area with regulatory approvals for their product developments is also expected to boost the growth of target market. For instance, in January 2021, Novartis AG announced the outcomes of its Phase II trial of the investigational product drug called Bimagrumab. The drug has shown potential for the indication of obesity. The drug is currently being studied in the Novartis pipeline. Therefore, the above-mentioned factors are anticipated to boost market growth over the forecast period.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Anti-obesity Drugs Market By Mechanism of Action, By Drug Type and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Anti-obesity Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Anti-obesity Drugs Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Anti-obesity Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Anti-obesity Drugs Market, By Mechanism of Action Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Peripherally Acting Drugs
        2. Centrally Acting Drugs

  • 8.   Global Anti-obesity Drugs Market, By Drug Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Prescription Drugs
        2. OTC Drugs

  • 9.   North America Anti-obesity Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Anti-obesity Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Anti-obesity Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Anti-obesity Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Arena Pharmaceuticals Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Alizyme
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Bayer AG
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Bristol-Myers Squibb
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Currax Pharmaceuticals LLC
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Eisai Co. Ltd
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. F. Hoffmann-La Roche AG
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. GlaxoSmithKline PLC
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. MerckCo. Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Norgine BV
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Novo Nordisk AS
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Orexigen Therapeutics
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Pfizer Inc.
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Rhythm Pharmaceuticals
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Takeda Pharmaceuticals
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Vivus Inc.
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Zafgan
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Zydus Cadila
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.   FutureWise SME Key Takeaway Points for Client

Related Market

Obesity Management Market

Read More

Obesity Treatment Market

Read More
Partner

Our Clients